Minimizing infection risks after paediatric organ transplants: Advice for practitioners
Posted: Mar 1 2013 | Reaffirmed: Feb 1 2016
The Canadian Paediatric Society gives permission to print single copies of this document from our website. For permission to reprint or reproduce multiple copies, please see our copyright policy.
Upton D Allen; Canadian Paediatric Society, Infectious Diseases and Immunization Committee
Paediatr Child Health 2013;18(3):143-8
Paediatric patients who have undergone an organ transplant face risks associated with different infectious diseases. Their susceptibility is increased by treatment with immunosuppressive medications. More of these patients are being cared for in community settings. This practice point provides guidance on key aspects in the prevention and treatment common infections.
Key Words: Antibiotics; Immunosuppression; Infection; Transplantation; Vaccines
The paediatric patient undergoing an organ transplant is at risk of acquiring various infectious diseases from three possible sources: the endogenous reactivation of latent pathogens (eg, herpes viruses); transmission from the donated organ or tissue; or transmission from within the community or health care setting. Clinicians practicing in community settings often provide care for these vulnerable patients before or after transplantation. Guidelines for the prevention and treatment of these infections were recently published and reviews have been written. This practice point summarizes key aspects of managing transplant patients, with a focus on issues likely to be encountered in community settings.
Preparing the patient
The pretransplant period should be used to improve a patient’s overall health and well-being as much as possible, with particular emphasis on optimizing vaccination status (Table 1). The likelihood of an adequate immune response improves when vaccines are administered before the onset of immune suppression. As a general rule, the interval between administering an inactivated vaccine and transplantation should be more than two weeks to allow for an adequate immune response.- The minimum interval between the last dose of a ‘live’ vaccine and onset of immune suppression should be four weeks.- Live vaccines (eg, measles vaccine) are relatively contraindicated after transplantation. Also, the patient’s household contacts should have received all age-appropriate vaccines for measles, mumps, rubella, varicella, pertussis, Haemophilus influenzae type b, meningococcal, pneumococcal, rotavirus, and the seasonal influenza vaccine. A second focus in the pretransplant period should be on identifying acute, chronic or latent infections in the transplant candidate as well as in prospective living donors. While this practice point concentrates primarily on the transplant candidate or recipient, clinicians will also need to work closely with their transplant centre and be familiar with protocols for living donor screening. Specific conditions may be determined by patient history (including risks associated with tuberculosis exposure, travel, living abroad, household pets, lifestyle and occupation), by the physical examination or by screening tests (Table 2). Pre-existing infections can contraindicate or delay transplantation. Detailed patient information is critical for assessing the risk of post-transplant infection and for guiding post-transplant prophylaxis (Table 3). Counselling on how to avoid high-risk exposures in the immediate pretransplant period (eg, around lifestyle, travel, food and water sources) should be provided to both recipient and donor.
Post-transplant infections to expect
In the first month
Greater than 95% of infections occurring in this critical period are similar to infections incurred by nonimmunosuppressed patients who have undergone a comparable surgical procedure.- The remaining are caused either by an infection that was present in the recipient before transplantation that was exacerbated by surgery, anesthesia and immunosuppressive therapy, or by an infection being transmitted by the allograft.
One to six months post-transplant
In this period, the effects of immune suppression become noticeable and may result in two types of opportunistic infections. In the first category are viral pathogens that are associated with latent or persistent infections, including cytomegalovirus (CMV), Epstein-Barr virus (EBV), human herpes virus 6, and hepatitis B and C viruses. Infection by these pathogens can be primary (typically acquired from the donor rather than from the community), a reactivation of latent pathogens, or reinfection with a new strain of the virus. Typical pathogens in the second category are Listeria monocytogenes, Aspergillus fumigatus and Pneumocystis jirovecii. Infection development with these organisms is aided by sustained immunosuppression with or without the immunomodulating effects of viral infections to create a net state of immunosuppression sufficient to increase susceptibility. Some organ transplants (eg, of the small bowel) carry higher risks of opportunistic infection compared with others (eg, the kidney) because immunosuppression is more intense.
More than six months post-transplant
Published data on infectious complications in this period are limited and may be biased toward serious infections that require hospitalization. Patients who are on maintenance immunosuppression and have good allograft function are likely to acquire the same community-acquired infections as healthy children (eg, common respiratory viruses). Some patients with poorer post-transplant outcomes (eg, acute or chronic immunosuppression, poor allograft function or a chronic viral infection) are at high risk for recurrent infections relating to uncorrected mechanical or anatomical problems (eg, implanted foreign material or an obstruction), as well as for opportunistic infections from P jirovecii, L monocytogenes, Cryptococcus neoformans, and Nocardia asteroides, among others.
Evaluation of the febrile transplant patient
Fever in the transplant patient may be due to a common childhood infection or to an infection that is unique to the transplant recipient. The timing of infection after transplantation provides guidance regarding the most likely pathogens. Evaluation and empirical therapy will depend on the clinical status of the patient and whether or not a source of infection has been identified.
When the examination is abnormal and the focus of infection is defined
Hospital admission may be indicated, depending on the clinical status of the patient and the site of infection. Diagnostic evaluation should include, at a minimum, a complete blood count and differential, and blood cultures. Additional investigations depend on the clinical focus and timing of presentation after transplantation.
When the examination is normal and no focus of infection is defined
Hospital admission is usually warranted if the patient is clinically unwell. Diagnostic evaluation is based on the differential diagnoses. Patients who feel well may not require admission, depending on the adequacy of available follow-up, their ability to return to the hospital promptly if a condition worsens, the degree of immune suppression and the interval since transplantation. Diagnostic evaluation should include, at a minimum, a complete blood count and differential, and blood and urine cultures. In the first months following a transplant, the site of infection often relates to the surgical procedures performed. Clinicians need to be aware of viral infections that are associated with fever but have no readily apparent focus of infection (eg, CMV and adenovirus). In the absence of an obvious benign source of fever, such patients should be managed in consultation with their transplant centre. When choosing antibiotics for infections (as appropriate), clinicians need to be aware of potential interactions between antibiotics and selected immunosuppressive drugs; Table 4 lists immunosuppressive agents, while Table 5 shows potential drug interactions.
Timing and schedule
Most transplant centres provide schedules for immunizing recently transplanted paediatric patients (Table 1). Usually, vaccines are not administered in the first six to 12 months following a transplant  with the exception of the seasonal inactivated influenza vaccine, which is administered no earlier than one month after transplantation and yearly thereafter. Clinicians should acquaint themselves with appropriate vaccination schedules. Also, vaccinating household contacts is a key strategy in protecting the vulnerable transplant recipient.
Vaccines that are contraindicated for immunosuppressed transplant patients are shown in Table 3. Some groups recommend giving measles, mumps and rubella vaccines in select low-risk patients with minimal immunosuppression.- Limited data exist for administering the varicella vaccine after transplantation.- However, most experts consider organ transplant to be a contraindication for the varicella vaccine and, in the event of exposure, susceptible individuals are candidates for varicella-zoster immune globulin. This issue underscores the importance of pretransplant vaccination. Vaccinating paediatric transplant candidates has been shown to sustain humoral immunity for at least two years, well beyond the period of peak immunosuppression.
Selected indicated vaccines
Pneumococcal vaccines: Transplant patients are considered to be at high-risk of invasive pneumococcal disease, with heart transplant recipients being particularly vulnerable.- Consequently, pneumococcal vaccine is one of the most important vaccines given to transplant recipients. Current recommendations are for sequential use of the 13-valent pneumococcal conjugate vaccine (with the number of doses depending on the age of the child) followed in eight weeks by the 23-valent vaccine.- Some organ transplant patients with functional or anatomical asplenia are candidates for long-term penicillin prophylaxis to prevent invasive pneumococcal disease.
Meningococcal vaccines: These vaccines may be safely administered using routine childhood schedules. The meningococcal conjugate quadrivalent vaccine (MCV), rather than the polysaccharide quadrivalent vaccine, should be used. Most experts agree there is no role for the polysaccharide vaccine at present. The meningococcal conjugate quadrivalent vaccine is not approved for children younger than 24 months of age.
Human papilloma virus vaccine: The human papilloma virus (HPV) vaccine can be safely administered after an organ transplant. While data are lacking to support the efficacy of HPV vaccine in recipients whose immune responses may be weaker than those of healthy individuals, the vaccine is strongly recommended for both female and male transplant patients given their particular risk of developing severe genital warts and potentially aggressive HPV-related malignancies.
Hepatitis B and A vaccines: Hepatitis B vaccine should be given according to the routine immunization schedule, but with double the usual dose. Hepatitis A vaccine is usually recommended for individuals with risk factors for hepatic disease other than transplantation (eg, chronic liver disease or epidemiological factors). However, some experts recommend hepatitis A vaccine even if other risk factors are absent because potentially hepatotoxic drugs may be used to treat immunosuppression.
Inactivated polio, Haemophilus influenzae type b and diphtheria, tetanus and acellular pertussis vaccines: These vaccines are all recommended, preferably before transplantation, in accordance with the routine schedule for children. If not previously received, Haemophilus influenzae type b vaccine should be given, regardless of age.
Influenza vaccine: Transplant recipients and all household and other close contacts should receive inactivated influenza vaccine yearly during the fall.
Community-acquired respiratory viruses
Paediatric organ transplant recipients are at risk for community-acquired respiratory viral infections, including respiratory syncytial virus, influenza viruses, human metapneumovirus, parainfluenza viruses and others. Guidelines for preventing and managing these infections were published recently,- and influenza management guidelines are published annually in Canada.
Post-transplant targets for antimicrobial prohylaxis
Transplant patients may require antimicrobial prophylaxis against Candida species, Aspergillus species, herpes group viruses (eg, herpes simplex, CMV, EBV), hepatitis B, P jirovecii, Toxoplasma gondii, Strongyloides, latent tuberculosis infection and other pathogens (Table 2). Of these infective agents, CMV and EBV consume the greatest resources in most paediatric transplant centres. Guidelines on the prevention and treatment of these conditions have been recently updated.-
Infection risks of daily living after a transplant
Besides providing information on the risks of immunosuppressive drugs (Table 4)  and their interactions with common antimicrobials (Table 5), clinicians need to counsel young transplant patients about infection risks associated with food and drinking water, pets and other animals, swimming and other water sports, fungal spores (eg, from gardening, farm buildings, construction sites, excavations, caves, marijuana and tobacco), mosquito bites, travel and sexual behaviour, as appropriate.
Inactivated (I)/ Live attenuated/(LA)
Recommended before transplantation
Recommended after transplantation
Routine for all transplant recipients
Haemophilus influenzae b (regardless of age)
Streptococcus pneumoniae (PCV 13/23-valent polysaccharide*)
Neisseria meningitidis (conjugate serogroup C and conjugate quadrivalent†)
Adapted from reference 2. *All required doses of conjugate vaccine should be given before polysaccharide vaccine. Children younger than 24 months of age are unlikely to respond to polysaccharide vaccine.†Conjugate quadrivalent vaccine is currently not licensed in children under 24 months of age. ‡The live attenuated vaccine is approved for healthy patients. It may be given to pretransplant patients who are healthy. If used, the vaccine should be administered two or more weeks before transplantation. §These vaccines are usually given at 12 months of age but are sometimes given as early as six months of age in children awaiting transplant. These vaccines must be given ≥4 weeks before transplantation. BCG Bacillus Calmette–Guérin; PCV Pneumococcal conjugate vaccine
Comments/action required for abnormal results
HIV-1 and -2 serology and antigen detection
Refer for HIV management if positive; some centres do not transplant
HTLV-1 and -2 serology
Refer for counselling if positive
Hepatitis A serology
Vaccinate if nonimmune and nontransplant risk factors are present; some experts recommend vaccination routinely
Hepatitis B serology
Obtain full panel of hepatitis B serology, including surface antigen and anticore antibody; vaccinate if nonimmune
Hepatitis C serology
Refer for counselling if positive
Hepatitis D serology
Obtain if hepatitis B surface antigen positive and test available
Obtain IgG; urine culture for seropositive infants <18 months of age; influences post-transplant management
Epstein-Barr virus serology
Viral capsid antigen and Epstein-Barr nuclear antigen; influences post-transplant management;
Herpes simplex virus serology
Influences post-transplant management
Varicella-zoster virus serology
Vaccinate seronegative candidates who have not been vaccinated previously at least four weeks before transplantation;
Toxoplasma gondii serology
Obtain in heart or heart-lung candidates; influences post-transplant management
Measles serology if vaccinated
If negative or not vaccinated, vaccinate; allow for at least four weeks between vaccine dose and transplantation
Mumps serology if vaccinated
If negative or not vaccinated, vaccinate; allow for at least four weeks between vaccine dose and transplantation
Rubella serology if vaccinated
If negative or not vaccinated, vaccinate; allow for at least four weeks between vaccine dose and transplantation
Obtain history of potential exposure; Mantoux test; IGRA being evaluated; intervention for latent TB may be required
Obtain if patient has lived in an endemic area; positive serology requires intervention with ivermectin treatment
Respiratory tract pathogens
Obtain sputum cultures from patients with cystic fibrosis and other lung transplant candidates;
Obtain as clinically indicated
Adapted from reference 2. *Maternal antibody may lead to false positive serological tests among infants <18 months of age, and false positive tests due to passively transfused antibody may be obtained after recent receipt of blood products; †A negative polymerase chain reaction (PCR) does not rule out latent infection in the infant. This is not an all-inclusive list. Other screening tests may be indicated for specific pathogens (eg, syphilis, and Kaposi’s sarcoma-associated herpesvirus [HHV8] for individuals from endemic areas. Generally, HHV8 seroprevalence rates are as follows: North America, Asia, northern Europe <5%; Mediterranean basin, Caribbean, Middle East 5% to 20%; Africa, Amazon basin >50%.(24) HTLV Human T-lymphotrophic virus; IgG Immunoglobulin G; IGRA Interferon gamma release assays; TB Tuberculosis
Target groups prophylaxis regimens/comments
Suggested duration of prophylaxis
Bacterial infection (post-operative wound infection
Duration will depend on the organ and nature of surgery
Stratification of risk based on CMV donor/recipient serostatus
Emerging data for valganciclovir in low-to-intermediate risk older children
Typically three months; some centres prophylax for shorter (two weeks) or longer (six months) periods
High-risk patients are D+R– patients*
Duration variable if antivirals with/without immune globulin are employed
High-risk patients only (eg, liver, intestinal transplants)
Up to four weeks depending on risk factors
Lung/heart lung recipients
Duration variable; up to four to six months, depending on risk
Typically six to 12 months, or if receiving steroids or if CD4 <200/mm3; for lung and small bowel transplant recipients, as well as patients with history of prior PJP infection or chronic CMV disease, lifelong prophylaxis may be indicated
TMP-SMX of some value for R+ patients
Adapted from reference 2. *D+R- denotes donor seropositive and recipient seronegative status; CMV Cytomegalovirus; EBV Epstein-Barr virus; PJP Pneumocystis jirovecii; TMP-SMX Trimethoprim-sulfamethoxazole
Trade name or
Mechanism of action/type of drug
Notable side effects
Rabbit antithymocyte globulin
Antibodies against thymus-derived epitopes (protein sites recognized by the immune system)
Anaphylaxis, infusion-related effects (eg, fever, chills, tachycardia, hypertension)
Equine antithymocyte globulin
Antibody to IL2 receptor (CD25)
Infusion related reactions (eg, fever, chills, hypotension), angioedema, pancytopenia
Inhibition of activator protein-1 and NF-κB
Hypertension, diabetes, salt/water retention, osteopenia, hyperlipidemia, Cushingoid features, hirsutism, acne, growth retardation
Hirsutism, gingival hyperplasia, nephrotoxicity, hypertension
Tremor, dose-dependent neuropathy, nephrotoxicity, hypertension, hyperglycemia
Mycophenolate mofetil (MMF)
Inhibition of purine biosynthesis and inhibition
Leukopenia, anemia, thrombocytopenia, gastrointestinal symptoms
Enteric coated mycophenolate sodium (EC-MPA)
Purine analog; inhibition of DNA synthesis
Leukopenia, anemia, thrombocytopenia
Arrest in cell cycle and differentiation
Delayed wound healing, aphthous ulcers, hyperlipidemia, bone marrow suppression, pneumonitis
*Pfizer, USA; †Novartis, USA; ‡Genentech, USA; §Astellas Pharma US Inc, USA; ¶Triton Pharma Inc, Canada. mTOR A serine/threonine protein kinase that has direct control of protein synthesis
Inducers (decrease levels of immunosuppressants)
Inhibitors (increase levels of immunosuppressants)
Degree of interaction
Interaction with erythromycin >
Caspofungin AUC (exposure) increased with cyclosporine
*Degree of inhibition/induction of CYP p450 enzymes is drug- and/or route-specific, affecting the degree of interaction with listed immunosuppressants. The above drug interactions do not preclude use of these antimicrobial agents. However, strategies to manage and monitor interactions/drug levels should be discussed with the transplant team before initiation. AUC Area under the curve; CYP Cytochrome p450
This practice point has been reviewed by the Canadian Paediatric Society’s Community Paediatrics Committee.
CPS INFECTIOUS DISEASES AND IMMUNIZATION COMMITTEE
Members: Robert Bortolussi MD (Past Chair); Natalie A Bridger MD; Jane C Finlay MD; Susanna Martin MD (Board Representative); Jane C McDonald MD; Heather Onyett MD; Joan L Robinson MD (Chair)
Liaisons: Upton D Allen MD, Canadian Pediatric AIDS Research Group; Michael Brady MD, Committee on Infectious Diseases, American Academy of Pediatrics; Janet Dollin MD, College of Family Physicians of Canada; Charles PS Hui MD, Committee to Advise on Tropical Medicine and Travel, Public Health Agency of Canada; Nicole Le Saux MD, IMPACT (Immunization Monitoring Program, ACTive); Dorothy L Moore MD, National Advisory Committee on Immunization (NACI); John S Spika MD, Public Health Agency of Canada
Consultant: Noni E MacDonald MD
Principal author: Upton D Allen MD
- Allen UD, Humar A, Limaye A, Michaels M, Miller R, eds. The American Society of Transplantation Special Issue: AST Infectious Diseases Guidelines, 2nd edn. Am J Transplant 2009;9(Supp 4):S1-281.
- Allen UD, Green M. Prevention and treatment of infectious complications after solid organ transplantation in children. Pediatr Clin North Am 2010;57(2):459-79.
- Public Health Agency of Canada. Immunization of immunocompromised persons. In Canadian Immunization Guide, Evergreen edn, 2012. www.phac-aspc.gc.ca/publicat/cig-gci/index-eng.php (Accessed February 12, 2013).
- American Academy of Pediatrics. Immunizations in special clinical circumstances – solid organ transplant recipients. In: Pickering LK, Baker CJ, Kimberlin DW, Lon SS, eds. Red Book: 2012 Report of the Committee on Infectious Diseases, 29th edn. Elk Grove Village: American Academy of Pediatrics, 2012:85.
- Fishman JA, Rubin RH. Infection in organ-transplant recipients. N Engl J Med 1998;338(24):1741-51.
- Rubin RH, Ikonen T, Gummert JF, Morris RE. The therapeutic prescription for the organ transplant recipient: The linkage of immunosuppression and antimicrobial strategies. Transpl Infect Dis 1999;1(1):29-39.
- Danzinger-Isakov L, Kumar D; AST Infectious Diseases Community of Practice. Guidelines for vaccination of solid organ transplant candidates and recipients. Am J Transplant 2009;9(Suppl 4):S258-62.
- Khan S, Erlichman J, Rand EB. Live virus immunization after orthotopic liver transplantation. Pediatr Transplant 2006;10(1):78-82.
- Shinjoh M, Miyairi I, Hoshino K, Takahashi T, Nakayama T. Effective and safe immunizations with live-attenuated vaccines for children after living donor liver transplantation. Vaccine 2008;26(52):6859-63.
- Weinberg A, Horslen SP, Kaufman SS, et al. Safety and immunogenicity of varicella-zoster virus vaccine in pediatric liver and intestine transplant recipients. Am J Transplant 2006;6(3):565-8.
- Prelog M, Zimmerhackl LB. Varicella vaccination in pediatric kidney and liver transplantation. Pediatr Transplant 2010;14(1):41-7.
- Barton M, Wasfy S, Melbourne T, et al. Sustainability of humoral responses to varicella vaccine in pediatric transplant recipients following a pretransplantation immunization strategy. Pediatr Transplant 2008;13(8):1007-13.
- Tran L, Hébert D, Dipchand A, Fecteau A, Richardson S, Allen U. Invasive pneumococcal disease in pediatric organ transplant recipients: A high-risk population. Pediatr Transplant 2005;9(2):183-6.
- Stovall SH, Ainley KA, Mason EO Jr, et al. Invasive pneumococcal infections in pediatric cardiac transplant patients. Pediatr Infect Dis 2001;20(10):946-50.
- Lin PL, Michaels MG, Green M, et al. Safety and immunogenicity of the American Academy of Pediatrics - recommended sequential pneumococcal conjugate and polysaccharide vaccine schedule in pediatric solid organ transplant recipients. Pediatrics 2005;116(1):160-7.
- Barton M, Wasfy S, Dipchand A, et al. Seven-valent pneumococcal conjugate vaccine in pediatric solid organ transplant recipients: A prospective study of safety and immunogenicity. Pediatr Infect Dis J 2009;28(8):688-92.
- Kumar D, Humar A. Respiratory viral infections in transplant and oncology patients. Infect Dis Clin North Am 2010;24(2):395-412.
- Ison MG, Michaels MG; AST Infectious Diseases Community of Practice. RNA respiratory viral infections in solid organ transplant recipients. Am J Transplant 2009;9(Suppl 4):S166-72.
- Avery RK, Michaels MG; AST Infectious Diseases Community of Practice. Strategies for safe living following solid organ transplantation. Am J Transplant. 2009;9(Suppl 4):S252-7.
- Aoki FY, UD Allen, Stiver HG, Evans, GA. The use of antiviral drugs for influenza: Guidance for practitioners, 2012-2013. www.ammi.ca/media/48038/14791_aoki_final.pdf.pdf (Accessed December 2, 2012).
- Allen U, Preiksaitis J; AST Infectious Diseases Community of Practice. Epstein-Barr virus and post-transplant lymphoproliferative disorder in solid organ transplant recipients. Am J Transplant 2009;9(Suppl 4):S87-96.
- Kotton CN, Kumar D, Caliendo AM, et al; Transplantation Society International CMV Consensus Group. International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. Transplantation 2010;89(7):779-95.
- Urshel S, Altamirano-Diaz LA, West LJ. Immunosuppression armamentarium in 2010: Mechanistic and clinical considerations. In: Ng V, Fend S, eds. Optimization of Ouctomes for Children after Solid Organ Transplantation. Pediatr Clin North Am 2010;57(2):433-57.
- Ho M. Human herpes virus 8 – let the transplantation physician beware. N Engl J Med 1998;339(19):1391-2.
Disclaimer: The recommendations in this position statement do not indicate an exclusive course of treatment or procedure to be followed. Variations, taking into account individual circumstances, may be appropriate. Internet addresses are current at time of publication.